The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

February 28, 2014

Conditions
Healthy
Interventions
DRUG

Maraviroc (5 days)

Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.

DRUG

Maraviroc and boceprevir (14 days)

From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.

Trial Locations (1)

H2W 1T8

Centre Hospitalier de l'Université de Montréal, Montreal

All Listed Sponsors
collaborator

Université de Montréal

OTHER

collaborator

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

collaborator

Toronto General Hospital

OTHER

lead

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

NCT01627717 - The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers | Biotech Hunter | Biotech Hunter